截至9月30日，特一药业股东户数5.81万，较上期增加10.11%；人均流通股6481股，较上期减少9.09%。 2025年1月-9月，特一药业实现营业收入6.92亿元，同比增长51.86%；归母净利润6521.71万元，同比增 长985.18%。 今年以来特一药业已经14次登上龙虎榜，最近一次登上龙虎榜为11月28日，当日龙虎榜净买入-1.90亿 元；买入总计2.21亿元 ，占总成交额比11.76%；卖出总计4.11亿元 ，占总成交额比21.89%。 资料显示，特一药业集团股份有限公司位于广东省台山市台城长兴路9、11号，成立日期2002年5月23 日，上市日期2014年7月31日，公司主营业务涉及主要从事中成药品、化学制剂药品、化学原料药的研 发、生产和销售。主营业务收入构成为：中成药61.00%，化学药制剂32.61%，化学原料药5.77%，化工 产品及其他0.61%。 特一药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：幽门螺杆概念、原料药、 NMN概念、抗流感、医药电商等。 12月23日，特一药业盘中下跌2.15%，截至09:45，报10.93元/股，成交5194.43万元，换手率1 ...

12月19日，兄弟科技盘中上涨2.09%，截至13:00，报6.36元/股，成交6065.29万元，换手率1.37%，总市 值72.68亿元。 分红方面，兄弟科技A股上市后累计派现3.90亿元。近三年，累计派现1.06亿元。 资金流向方面，主力资金净流入288.34万元，特大单买入140.52万元，占比2.32%，卖出0.00元，占比 0.00%；大单买入781.91万元，占比12.89%，卖出634.09万元，占比10.45%。 兄弟科技今年以来股价涨49.65%，近5个交易日涨0.00%，近20日跌1.40%，近60日跌10.42%。 今年以来兄弟科技已经9次登上龙虎榜，最近一次登上龙虎榜为9月25日，当日龙虎榜净买入-5801.97万 元；买入总计1.27亿元 ，占总成交额比7.06%；卖出总计1.85亿元 ，占总成交额比10.28%。 资料显示，兄弟科技股份有限公司位于浙江省海宁市海洲街道学林街1号，成立日期2001年3月19日，上 市日期2011年3月10日，公司主营业务涉及维生素、皮革化学品、香精香料、原料药和催化新材料等产 品的研发、生产与销售。主营业务收入构成为：医药食品58.88%，特种化学 ...

Group 1 - The core viewpoint of the news is that Yinxin Technology's stock has experienced fluctuations, with a current price of 9.23 CNY per share and a market capitalization of 4.373 billion CNY, while the company has shown significant revenue and profit growth year-to-date [1][2]. Group 2 - As of September 30, Yinxin Technology had 34,600 shareholders, an increase of 1.87% from the previous period, with an average of 13,204 circulating shares per shareholder, a decrease of 0.97% [2]. - For the period from January to September 2025, Yinxin Technology achieved operating revenue of 1.653 billion CNY, representing a year-on-year growth of 16.75%, and a net profit attributable to shareholders of 84.714 million CNY, which is an increase of 116.39% year-on-year [2]. Group 3 - Since its A-share listing, Yinxin Technology has distributed a total of 177 million CNY in dividends, with no dividends paid in the last three years [3].

Core Viewpoint - The stock price of Te Yi Pharmaceutical has shown significant growth this year, with a year-to-date increase of 56.84% and a recent surge of 14.52% over the last five trading days [2] Group 1: Stock Performance - As of November 27, Te Yi Pharmaceutical's stock price rose by 2.57% to 13.96 CNY per share, with a trading volume of 8.83 billion CNY and a turnover rate of 17.18%, resulting in a total market capitalization of 71.62 billion CNY [1] - The company has appeared on the stock market's "Dragon and Tiger List" 12 times this year, with the most recent appearance on November 26, where it recorded a net buy of -19.39 million CNY [2] Group 2: Financial Performance - For the period from January to September 2025, Te Yi Pharmaceutical achieved a revenue of 6.92 billion CNY, reflecting a year-on-year growth of 51.86%, while the net profit attributable to shareholders reached 65.22 million CNY, marking an impressive increase of 985.18% [2] - The company has distributed a total of 10.59 billion CNY in dividends since its A-share listing, with 3.56 billion CNY distributed over the past three years [3] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2] - Among the top ten circulating shareholders, the third-largest is the Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A, holding 3.33 million shares, while the fourth is the Xingquan Hu-Shen 300 Index Enhanced A, holding 1.92 million shares, both unchanged from the previous period [3]

Core Viewpoint - Brother Technology's stock has shown significant volatility, with a year-to-date increase of 55.06% but a recent decline in the last five trading days by 5.72% [1] Financial Performance - For the period from January to September 2025, Brother Technology achieved a revenue of 2.725 billion yuan, representing a year-on-year growth of 4.84% [2] - The net profit attributable to the parent company for the same period was 101 million yuan, showing a substantial increase of 211.75% year-on-year [2] Stock Market Activity - As of November 25, Brother Technology's stock price was 6.59 yuan per share, with a market capitalization of 7.531 billion yuan [1] - The stock has been on the龙虎榜 (a list of stocks with significant trading activity) nine times this year, with the most recent appearance on September 25, where it recorded a net buy of -58.0197 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders for Brother Technology increased to 101,600, a rise of 61.51% from the previous period [2] - The average number of circulating shares per shareholder decreased by 38.08% to 6,906 shares [2] Dividends and Institutional Holdings - Since its A-share listing, Brother Technology has distributed a total of 390 million yuan in dividends, with 106 million yuan distributed over the last three years [3] - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF holds 14.1311 million shares, an increase of 5.0455 million shares from the previous period [3]

Core Viewpoint - The stock of Kingdawei has experienced a decline recently, with a notable drop in trading volume and fluctuations in shareholder numbers, despite a year-to-date increase in stock price and significant growth in revenue and net profit [1][2]. Financial Performance - For the period from January to September 2025, Kingdawei achieved a revenue of 2.604 billion yuan, representing a year-on-year growth of 11.16% [2]. - The net profit attributable to shareholders for the same period was 361 million yuan, showing a substantial increase of 63.47% compared to the previous year [2]. Stock Market Activity - As of November 21, Kingdawei's stock price was 18.96 yuan per share, with a market capitalization of 11.564 billion yuan [1]. - The stock has increased by 28.98% year-to-date, but has seen a decline of 9.11% over the last five trading days [1]. Shareholder Information - As of September 30, the number of shareholders for Kingdawei was 36,300, a decrease of 10.95% from the previous period [2]. - The average number of circulating shares per shareholder increased by 12.29% to 16,817 shares [2]. Dividend Distribution - Kingdawei has distributed a total of 2.761 billion yuan in dividends since its A-share listing, with 488 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3]. - The Southern CSI 1000 ETF and Huaxia CSI 1000 ETF were among the top ten circulating shareholders, with slight changes in their holdings [3].

Core Viewpoint - The stock of Te Yi Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 35.94%, indicating volatility in its market performance [1]. Company Performance - As of September 30, 2025, Te Yi Pharmaceutical reported a revenue of 6.92 billion yuan, representing a year-on-year growth of 51.86%, and a net profit attributable to shareholders of 652.17 million yuan, which is a significant increase of 985.18% compared to the previous year [2]. - The company has distributed a total of 1.059 billion yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]. Stock Market Activity - The stock price of Te Yi Pharmaceutical is currently at 12.10 yuan per share, with a trading volume of 2.60 billion yuan and a turnover rate of 5.62%, leading to a total market capitalization of 6.207 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" 11 times this year, with the most recent appearance on November 17, where it recorded a net buy of -733.44 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2]. - Among the top ten circulating shareholders, notable positions include the "Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A" and "Xingquan Hu-Shen 300 Index Enhanced (LOF) A," which maintained their holdings [3].

Core Viewpoint - The stock of Zhongsheng Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a total market capitalization of 18.936 billion yuan, despite an overall increase of 86.44% year-to-date [1] Financial Performance - For the period from January to September 2025, Zhongsheng Pharmaceutical reported a revenue of 1.889 billion yuan, a year-on-year decrease of 1.01%, while the net profit attributable to shareholders increased by 68.40% to 251 million yuan [2] - The company has cumulatively distributed 2.019 billion yuan in dividends since its A-share listing, with 502 million yuan distributed over the past three years [3] Stock Market Activity - The stock has seen significant trading activity, with a net outflow of 67.267 million yuan in major funds recently, and it has appeared on the trading leaderboard seven times this year [1] - The stock price has fluctuated, with a recent 5-day decline of 5.75% and a 20-day increase of 20.89% [1] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 18.90% to 72,900, while the average number of circulating shares per person increased by 23.31% to 10,445 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited and several funds from Xingquan, indicating a mix of new and increasing positions among major shareholders [3]

Core Viewpoint - The stock of Kingdawei has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 33.27%, indicating volatility in its market performance [1]. Financial Performance - As of September 30, Kingdawei reported a revenue of 2.604 billion yuan, representing a year-on-year growth of 11.16% [2]. - The net profit attributable to shareholders for the same period was 361 million yuan, showing a significant increase of 63.47% year-on-year [2]. Shareholder Information - The number of shareholders as of September 30 is 36,300, a decrease of 10.95% from the previous period [2]. - The average circulating shares per person increased by 12.29% to 16,817 shares [2]. Dividend Distribution - Kingdawei has distributed a total of 2.761 billion yuan in dividends since its A-share listing, with 488 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 7.7408 million shares, an increase of 803,600 shares from the previous period [3]. - The seventh largest circulating shareholder is Southern CSI 1000 ETF, holding 2.7924 million shares, which decreased by 20,500 shares [3]. - The tenth largest circulating shareholder is Huaxia CSI 1000 ETF, holding 1.6575 million shares, with a reduction of 4,900 shares [3].

Core Points - The stock price of Hongyang fell by 2.08% on November 19, reaching 6.11 CNY per share, with a total market capitalization of 7.931 billion CNY [1] - The company has seen a year-to-date stock price increase of 2.35%, but has experienced declines of 3.17% over the last five trading days, 6.43% over the last twenty days, and 11.83% over the last sixty days [1] - Hongyang's main business involves the research and production of new environmentally friendly pesticides, with pesticide sales accounting for 96.95% of its revenue [1][2] Financial Performance - For the period from January to September 2025, Hongyang reported operating revenue of 2.328 billion CNY, a year-on-year decrease of 13.87%, and a net profit attributable to shareholders of -272 million CNY, a year-on-year decrease of 1115.05% [2] - The company has cumulatively distributed 1.146 billion CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Shareholder Information - As of October 20, Hongyang had 43,300 shareholders, a decrease of 2.91% from the previous period, with an average of 22,852 circulating shares per shareholder, an increase of 2.99% [2]